Federal Circuit Affirms USPTO: Diagnostic Testing Patent Ruled Unpatentable in Haines v. Brent

Introduction

In a decisive ruling that reinforces the USPTO’s gatekeeping authority over diagnostic method patents, the U.S. Court of Appeals for the Federal Circuit affirmed the agency’s rejection of a diagnostic testing patent application in In re: Robyn Aylor Haines, Case No. 24-2338. The court’s May 15, 2025 decision, issued just 237 days after the appeal was filed, sends a clear signal to patent applicants in the diagnostics space: patentability standards at the Federal Circuit remain rigorous, and pro se or non-traditional prosecution strategies face steep uphill battles.

The case centered on U.S. Patent Application No. 12/925,221 (published as US20110105856A1), covering a diagnostic testing invention. With the USPTO Acting Director named as respondent, the outcome underscores the deference appellate courts extend to agency determinations on patentability. For patent attorneys prosecuting diagnostic method claims, IP professionals managing biomedical portfolios, and R&D teams developing clinical diagnostics, this ruling offers critical lessons in claim strategy, prosecution diligence, and appellate risk.

Case Overview

The Parties

The Patent at Issue

The appeal centered on U.S. Patent Application No. 12/925,221 (published as US20110105856A1), covering a diagnostic testing invention. Specific claim language from the public record would detail the scope; however, based on the Federal Circuit’s affirmance of an unpatentability finding, the claims likely encountered rejections grounded in subject matter eligibility, obviousness, or enablement—the most common bases for USPTO rejection of diagnostic method applications post-*Mayo Collaborative Services v. Prometheus Laboratories* (2012).

• • Application Number: US12/925,221
• • Publication Number: US20110105856A1
• • Technology Area: Diagnostic testing methodology
• • Proceeding Type: Invalidity/Cancellation Action – Patentability challenge

Litigation Timeline & Procedural History

The appeal was filed on September 20, 2024, in the District of Columbia circuit jurisdiction, and adjudicated before the Court of Appeals for the Federal Circuit — the exclusive appellate forum for USPTO patent appeals under 35 U.S.C. § 141. The case resolved in approximately eight months, consistent with the Federal Circuit’s standard briefing and decisional timelines for ex parte patent appeals, which typically do not require oral argument or extensive evidentiary proceedings.

The relatively swift resolution suggests the panel found the USPTO’s patentability analysis well-supported on the existing record, requiring no remand for further factual development. The absence of a named chief judge in case records is consistent with Federal Circuit panel assignments in straightforward ex parte matters.

The Verdict & Legal Analysis

Outcome

The Federal Circuit affirmed the USPTO’s determination that the subject patent application claims are unpatentable. The court’s language was unambiguous: “We have considered Haines’s other arguments and find them unpersuasive. For the foregoing reasons, we affirm.” No damages were at issue, as this was a patentability proceeding rather than an infringement action. No injunctive relief applied.

The basis of termination is recorded as Unpatentable — meaning the applicant’s claims failed to satisfy the statutory requirements for patent protection, and the application will not issue as a granted patent.

Verdict Cause Analysis

This case falls under the Invalidity/Cancellation Action category with a Patentability verdict cause. In the context of a Federal Circuit appeal from USPTO rejection, this framing indicates the applicant challenged the Patent Trial and Appeal Board’s (PTAB) affirmance of an examiner’s rejection, which the Federal Circuit then reviewed under an administrative law standard — affirming if the agency’s decision was supported by substantial evidence and not arbitrary or capricious.

Diagnostic testing patents face heightened scrutiny under the *Mayo/Alice* framework, which bars patent protection for claims directed to laws of nature, natural phenomena, or abstract ideas without an inventive concept that transforms the claimed subject matter into patent-eligible application. While the specific rejection basis is not detailed in available case data, diagnostic method claims in this technology space routinely encounter §101 subject matter eligibility rejections, §103 obviousness challenges, or §112 enablement/written description issues.

The court’s dismissal of Haines’s “other arguments” as unpersuasive indicates the applicant raised multiple theories on appeal — a common strategy when primary patentability arguments have been exhausted — none of which created reversible error in the Federal Circuit’s assessment.

Legal Significance

This decision carries precedential weight for several reasons:

• • Deference doctrine reinforced: The Federal Circuit’s swift affirmance demonstrates continued deference to USPTO factual findings on patentability, particularly in diagnostic method applications.
• • Pro se prosecution risk: The case highlights the compounding risks of self-representation in complex patent appeals, where procedural missteps and inadequate claim construction arguments can prove fatal.
• • Diagnostic patent landscape: The ruling contributes to a pattern of Federal Circuit decisions narrowing the patentable scope of diagnostic testing methods, consistent with post-*Mayo* jurisprudence.

Industry & Competitive Implications

The diagnostic testing sector — encompassing molecular diagnostics, point-of-care testing, and clinical laboratory methodologies — remains one of the most patent-intensive and legally contested technology areas in life sciences IP. The Federal Circuit’s affirmance in *Haines v. Brent* reflects a broader regulatory and judicial trend constraining diagnostic method patents that do not demonstrate sufficient inventive application beyond natural biological relationships or abstract correlations.

For independent inventors and small diagnostic companies, this outcome illustrates the resource and strategic disadvantage of pursuing patent protection without experienced prosecution counsel, particularly against a USPTO that has refined its *Mayo*-framework rejection practices over more than a decade.

Larger diagnostics players with established prosecution teams and claim-drafting strategies designed around §101 pitfalls are better positioned to secure enforceable protection. Companies monitoring this space should track Federal Circuit diagnostic patent decisions as leading indicators of PTAB review standards and examination policy shifts.

The case also reflects a licensing market reality: unpatentable diagnostic method claims cannot serve as leverage in licensing negotiations, underscoring the importance of patentability clearance before commercialization investment.